Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.64 |
| ▸ | NPC1 | O15118 | 14/20 | 0.57 |
| ▸ | RAB9A | P51151 | 14/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | CCR6 | P51684 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23010588 | 0.88 | TP53 (0.51) | MAPTTP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19321443 | 0.88 | RAB9A (0.68) | MAPTTP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14046555 | 0.84 | NPC1 (0.74) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3232592 | 0.84 | SCN4A (0.61) | MAPTTP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3468735 | 0.84 | AR (0.70) | MAPTTP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8233692 | 0.84 | RAB9A (0.70) | MAPTTP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14852353 | 0.84 | RAB9A (0.76) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3468767 | 0.81 | MAPT (0.65) | MAPTTP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15086781 | 0.81 | MAPT (0.57) | MAPTTP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14046554 | 0.80 | MAPT (0.51) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458447-B1 | PIPERAZINYL METHANONE NAAA INHIBITORS | UNIV CALIFORNIA (US) | 2023-11-29 | — | — | EP | disclosed |
| US-8940716-B2 | Bicyclic heteroaryl compounds as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| US-20130053345-A1 | BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053345-A1 | BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS | GPR119, GPR139, GPR4 | MAPT 1165/4885TP53 4228/4885NPC1 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.